Phase II study of carboplatin–paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024

Objectives Only a few prospective studies have been conducted to examine the efficacy and safety of systemic chemotherapy for patients with pulmonary sarcomatoid carcinomas (PSCs). There is, thus, a crucial need to develop novel treatment strategies for this rare tumor. Patients and methods Chemothe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2022-04, Vol.27 (4), p.676-683
Hauptverfasser:	Oizumi, Satoshi, Takamura, Kei, Harada, Toshiyuki, Tachihara, Motoko, Morikawa, Naoto, Honda, Ryoichi, Watanabe, Satoshi, Asao, Tetsuhiko, Kunisaki, Mamoru, Fukuhara, Tatsuro, Noro, Rintaro, Kikuchi, Eiki, Tsutani, Yasuhiro, Tenma, Toshiyuki, Kobayashi, Kunihiko, Dosaka-Akita, Hirotoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Bevacizumab Bevacizumab - adverse effects Cancer Research Carboplatin Carboplatin - adverse effects Carcinoma Carcinoma - drug therapy Chemotherapy Clinical trials Cytotoxicity Disease control Hematology Humans Lung cancer Lung carcinoma Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medicine Medicine & Public Health Monoclonal antibodies Oncology Original Article Paclitaxel Paclitaxel - adverse effects Patients Prospective Studies Surgical Oncology Survival Targeted cancer therapy Tumors UMIN UMIN000008707
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!